Agilent, GKSP-312, AdvanceBio APTS G2S2 α(2,6) / A2G2S(6)2 N-glycan Standard

AdvanceBio APTS G2S2 α(2,6) / A2G2S(6)2 N-glycan Standard. N-glycan (di-sialylated, galactosylated biantennary) labeled with 8-aminopyrene-1,3,6-trisulfonate (APTS), for use as a qualitative standard in applications such as capillary electrophoresis (CE). Alternative glycan names: A2G(4)2S(6)2, A2G2S2, A2 (α2,6).

Specifications:
Chemical Structure:
Label: APTS
Monoisotopic Mass: MWGlycan + 440.9647 = 2663.7477
Name: G2S2 (α2,6)
Oxford Name: A2G(4)2S(6)2
Standard Type: Complex-type Native N-Glycan
Unit: 60 pmol

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
The AdvanceBio APTS G2S2 α(2,6) / A2G2S(6)2 N-glycan Standard is a high-purity, well-characterized reference material designed for advanced glycan analysis in pharmaceutical and biopharmaceutical research. Optimized for applications such as glycoprotein characterization, quality control, and method development, this standard provides confidence in the identification and quantitation of complex biantennary, sialylated N-glycan structures featuring α(2,6) and A2G2S(6)2 linkages. Labeled with 8-aminopyrene-1,3,6-trisulfonic acid (APTS), the standard delivers strong fluorescent signal and precise migration for capillary electrophoresis and HILIC-UPLC analyses. It is particularly valuable for benchmarking peak identification and validating analytical workflows when assessing glycosylation profiles of therapeutic antibodies and other glycoproteins. This reference standard is compatible with Agilent’s full suite of glycan analysis solutions, including the 1290 Infinity II LC systems, AdvanceBio Glycan Mapping columns, and the CE 7100 Capillary Electrophoresis System. It is also suitable for use with other major platforms that support APTS-labeled glycan detection. Utilizing this standard allows researchers and quality control laboratories to ensure data accuracy, reproducibility, and compliance with regulatory expectations in biotherapeutic development and lot release testing.